Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease - Jain, Nishank; Corken, Adam; Arthur, John M.; Ware, Jerry; Arulprakash, Narenraj; Dai, Junqiang; Phadnis, Milind A.; Davis, Otis; Rahmatallah, Yasir; Mehta, J.L.; Hedayati, S. Susan; Smyth, Susan (Vascular pharmacology, 2023)
Keywords: Adenosine; Cardiovascular; Chronic kidney disease; Clopidogrel; Clopidogrel - adverse effects; Female; Humans; Inflammation; Inflammation - diagnosis; Inflammation - drug therapy; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors - therapeutic use; Platelets; Renal Insufficiency, Chronic - diagnosis; Renal Insufficiency, Chronic - drug therapy; Thrombosis; Ticagrelor; Ticagrelor - adverse effects; Ticlopidine - adverse effects; Treatment Outcome; RCT; CAD; Chronic kidney disease; Inflammation; PLATO; GSNCA; ANCOVA; SD; GFR; Clopidogrel; Platelets; Ticagrelor; UACR; CKD; DAPT; LCMS; coronary artery disease; dual antiplatelet therapy; glomerular filtration rate; gene sets net correlations analysis; randomized controlled trial; urine albumin-to-creatinine ratio; liquid chromatography mass spectrometry; Platelet Inhibition and Patient Outcomes; analysis of covariance; standard deviation